Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.10) by 1100 percent. This is a 78.18 percent increase over losses of $(4.95) per share from the same period last year. The company reported quarterly sales of $5.686 million which beat the analyst consensus estimate of $1.875 million by 203.25 percent. This is a 1.25K percent increase over sales of $421.000 thousand the same period last year.